Back to top
more

Amphastar Pharmaceuticals (AMPH)

(Real Time Quote from BATS)

$41.88 USD

41.88
106,453

-0.56 (-1.32%)

Updated May 16, 2024 12:57 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 21% (52 out of 250)

Industry: Medical - Generic Drugs

Better trading starts here.

Zacks News

Zacks.com featured highlights include PDD Holdings, Amphastar Pharmaceuticals and Suzano

PDD Holdings, Amphastar Pharmaceuticals and Suzano are part of the Zacks Screen of the Week article.

Tirthankar Chakraborty headshot

3 Profitable Stocks Worth Investing in Using Net Income Ratio

PDD Holdings (PDD), Amphastar Pharmaceuticals (AMPH) and Suzano (SUZ) are some of the top picks with a high net income ratio.

Amphastar Pharmaceuticals (AMPH) Is Up 0.54% in One Week: What You Should Know

Does Amphastar Pharmaceuticals (AMPH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Factors That Make HCA Healthcare (HCA) a Lucrative Bet Now

HCA Healthcare (HCA) remains well-poised for growth on the resumption of elective surgeries, acquisitions and strong cash-generation abilities.

3 Reasons Growth Investors Will Love Amphastar (AMPH)

Amphastar (AMPH) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?

Here is how Amphastar Pharmaceuticals (AMPH) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

Tirthankar Chakraborty headshot

4 Top-Ranked Profitable Stocks to Buy Using Net Income Ratio

PDD Holdings Inc. (PDD), Tecnoglass (TGLS), Amphastar Pharmaceuticals (AMPH) and Axon Enterprise (AXON) have been selected as the top picks with a high net income ratio.

Centene (CNC) Divests Apixio to Boost Its Core Business

Centene (CNC) completes the sale of Apixio to New Mountain Capital in a bid to dispose of non-core assets and grow its core Managed Care business.

Centene (CNC) to Provide Managed Care for SoonerSelect Program

Centene (CNC) wins managed care contract to serve people in Oklahoma through the SoonerSelect and SoonerSelect Children's Specialty Plan programs.

Here is Why Growth Investors Should Buy Amphastar (AMPH) Now

Amphastar (AMPH) possesses solid growth attributes, which could help it handily outperform the market.

Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?

Here is how Amphastar Pharmaceuticals (AMPH) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

Zacks.com featured highlights include Tecnoglass, Amphastar Pharmaceuticals, Turkcell Iletisim Hizmetleri, and Copa Holdings

Tecnoglass, Amphastar Pharmaceuticals, Turkcell Iletisim Hizmetleri, and Copa Holdings are part of the Zacks Screen of the Week article.

Tirthankar Chakraborty headshot

4 Solid Profitable Stocks to Invest in Using Net Income Ratio

Tecnoglass (TGLS), Amphastar Pharmaceuticals (AMPH), Turkcell Iletisim Hizmetleri (TKC) and Copa Holdings (CPA) have been selected as the top picks with a high net income ratio.

Tenet Healthcare (THC) Gains 42.1% YTD: More Room to Run?

Tenet Healthcare's (THC) aim to boost USPI's network through continuous buyouts is positioning the company well for growth.

Factors That Make Ensign Group (ENSG) a Lucrative Bet Now

Ensign Group (ENSG) is well-poised for growth on increasing service revenues, an expanding healthcare portfolio and a strong capital position.

Here's Why You Should Hold UnitedHealth Group (UNH) Stock Now

Membership growth, expanding government business and improving operating margin poise UnitedHealth Group (UNH) well for growth.

Zacks Industry Outlook Highlights Amphastar, Dr. Reddy's and Teva Pharmaceutical

Amphastar, Dr. Reddy's and Teva Pharmaceutical have been highlighted in this Industry Outlook article.

Looking for a Growth Stock? 3 Reasons Why Amphastar (AMPH) is a Solid Choice

Amphastar (AMPH) possesses solid growth attributes, which could help it handily outperform the market.

Sundeep Ganoria  headshot

3 Generic Drug Stocks to Watch Amid Macro Headwinds

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.

Is Amphastar Pharmaceuticals (AMPH) Outperforming Other Medical Stocks This Year?

Here is how Amphastar Pharmaceuticals (AMPH) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

Amphastar (AMPH) Is a Great Choice for 'Trend' Investors, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Amphastar (AMPH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings and Revenue Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of 37.78% and 7.30%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Bausch Health (BHC) Misses Q1 Earnings and Revenue Estimates

Bausch (BHC) delivered earnings and revenue surprises of -30.67% and 0.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?

Here is how Amphastar Pharmaceuticals (AMPH) and Addus HomeCare (ADUS) have performed compared to their sector so far this year.

Zacks.com featured highlights Amphastar, Alpha Metallurgical and Riley Exploration

Amphastar, Alpha Metallurgical and Riley Exploration have been highlighted in this Screen of The Week article.